NE-3107 Alzheimer's, Parkinson's data boost Biovie

BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer's Disease

BioVie's NE3107 Demonstrates Potential Improvements in

Multimorbid diseases cluster in predictable ways: study, 2021-03-19

Changes in microbiome impact neurodegeneration in Alzheimer's model

NE-3107 Alzheimer's, Parkinson's data boost Biovie

BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

Aquinnah reports preclinical findings with lead compound for Alzheimer's disease

BioVie reports protocol deviations in Phase III Alzheimer's trial - Clinical Trials Arena

Analysis and data insight

Intercept heads for FDA talks to 'Regenerate' filing for NASH hopeful obeticholic acid

Antoxa and Swiftpharma collaborate to advance plant-made antibody against ricin exposure

Connex Biomedical Inc.

NE-3107 Alzheimer's, Parkinson's data boost Biovie

mast cell-mediated diseases

Nitric oxide-modified proteins reveal sex differences in Alzheimer's